相关实验视频

Updated: Jul 26, 2025

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Published on: October 28, 2022

一项集成的in silico和in vitro研究确定了Leishmania donovani MAP激酶12作为可能的毒性因子

Priyanka H Mazire¹, Amit Roy¹

¹Department of Biotechnology, Savitribai Phule Pune University, Ganeshkhind Road, Pune 411007, India.

International immunopharmacology

|June 17, 2023

概括

内脏莱什曼病的耐药性需要新的治疗方法. 研究人员确定了L. donovani MAPK12 (LdMAPK12) 作为这种严重的寄生虫疾病的潜在毒性因子和药物标.

科学领域:

寄生虫学的寄生虫学
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

内脏莱什曼病 (VL) 是一种严重的,危及生命的疾病,由Leishmania donovani.引起.
目前对VL的治疗受到副作用,成本和日益增长的抗药性限制.
线素激活蛋白激酶 (MAPKs) 是细胞过程的关键调节者,并代表潜在的治疗点.

研究的目的:

研究L. donovani MAPK12 (LdMAPK12) 在寄生虫毒性中的作用.
评估LdMAPK12作为内脏莱什曼病的潜在药物标.

主要方法:

对LdMAPK12的序列分析和与人类MAPKs的比较.
在不同的寄生虫阶段 (前列腺炎和前列腺炎) 中对LdMAPK12的表达分析.
在不同的细胞因子条件下研究巨细胞中的LdMAPK12表达.

主要成果:

LdMAPK12序列与人类的MAPK不同,并且在Leishmania物种中得到保护.
LdMAPK12在前乳腺和前乳腺阶段均表达.
病毒性元循环性前列腺体表现出比病毒性形式更高的LdMAPK12表达.
支持炎症的细胞因子降低了LdMAPK12的表达,而抗炎症的细胞因子增加了巨细胞的表达.

结论:

LdMAPK12可能是Leishmania donovani中的毒性因子.
LdMAPK12代表了一个有希望和可信的药物标,用于开发新的内脏莱什曼病治疗方法.

关键词:

细胞因子刺激细胞因子刺激高通道促进了巨乳的生长.在LdMAPK12中使用.低通道促使乳腺增生.转环性促性质激素是转环性促性质的.病毒性病毒性

更多相关视频

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites

Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites

Published on: March 16, 2018

相关概念视频

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...